Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 4 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 4 of 8.)

DateHeadlineEventSource5-minTo close
Lilly's Ebglyss® for moderate-to-severe atopic dermatitis (eczema) listed on Quebec's public drug formularyPress releaseCanada Newswire+0.09%-3.13%
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's diseasePress releasePR Newswire-0.27%+0.06%
U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerPress releasePR Newswire+0.09%-0.03%
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in TexasPress releasePR Newswire+0.04%+0.38%
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetesPress releasePR Newswire+1.29%+0.33%
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trialPress releasePR Newswire+0.24%-0.06%
Lilly announces plans to build $5 billion manufacturing facility in VirginiaPress releasePR Newswire-0.00%+1.33%
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of MedicinePress releasePR Newswire+0.24%-0.06%
Lilly to participate in Bernstein's 2nd Annual Healthcare ForumPress releasePR Newswire-0.25%+0.26%
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain healthPress releasePR Newswire+0.57%+2.28%
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investmentPress releasePR Newswire+0.57%+2.28%
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLLPress releasePR Newswire-0.40%+1.22%
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancersPress releasePR Newswire+0.18%+0.90%
Defiance Launches LLYZ: The First 2X Short ETF for Eli LillyPress releaseGlobeNewswire+0.13%+0.88%
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapyPress releasePR Newswire-0.14%-0.38%
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesityPress releasePR Newswire+1.25%+3.09%
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare ConferencePress releasePR Newswire-0.10%-2.20%
Lilly to participate in Wells Fargo 20th Annual Healthcare ConferencePress releasePR Newswire+0.11%-0.71%
Anne White to Retire as Executive Vice President and President, Lilly NeurosciencePress releasePR Newswire-0.90%+0.74%
Form 8-K ELI LILLY & Co For: Aug 18SEC filing · Form 8-KSEC EDGAR+0.73%+0.66%
Form 10-Q ELI LILLY & Co For: Jun 30SEC filing · Form 10-QSEC EDGAR-0.90%-0.35%
Form 8-K ELI LILLY & Co For: Aug 07SEC filing · Form 8-KSEC EDGAR-2.12%-4.96%
Lilly reports second-quarter 2025 financial results and raises guidancePress releasePR Newswire-2.12%-4.96%
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesityPress releasePR Newswire-2.12%-4.96%
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart diseasePress releasePR Newswire+1.66%-0.66%
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's diseasePress releasePR Newswire-0.19%-1.78%
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLLPress releasePR Newswire-1.50%—
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's diseasePress releasePR Newswire+0.37%+0.33%
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPress releasePR Newswire+0.37%+0.33%
Lilly and Verve announce expiration of Verve tender offerPress releasePR Newswire+0.24%+0.51%
Lilly confirms date and conference call for second-quarter 2025 financial results announcementPress releasePR Newswire+0.15%+0.71%
IBJ Media Releases Fourth Annual Indiana 250 List of Influential HoosiersPress releasePR Web+0.54%+2.42%
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free FormulationPress releaseCanada Newswire+0.23%-3.73%
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's diseasePress releasePR Newswire+0.58%+0.19%
Lilly declares third-quarter 2025 dividendPress releasePR Newswire-0.10%+0.31%
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsPress releasePR Newswire+2.41%+0.01%
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of MedicinePress releasePR Newswire+2.41%+0.01%
Form 11-K ELI LILLY & Co For: Dec 31SEC filing · Form 11-KSEC EDGAR+2.41%+0.01%
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPress releasePR Newswire-1.28%-1.22%
Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy SolutionsPress releasePR Newswire-1.03%-1.72%
Allterum Awarded Third Major CPRIT Grant to Accelerate Therapeutic DevelopmentPress releasePR Web-0.13%+0.42%
Lilly presents first clinical data for its investigational, next-generation FRa targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual MeetingPress releasePR Newswire+0.71%+2.00%
Lilly to participate in Goldman Sachs 46th Annual Global Health Care ConferencePress releasePR Newswire-0.12%+1.81%
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific SessionsPress releasePR Newswire-0.64%+1.75%
Lilly to expand its pain pipeline with acquisition of SiteOne TherapeuticsPress releasePR Newswire+0.38%+0.77%
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingPress releasePR Newswire+0.72%+0.52%
Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's diseasePress releasePR Newswire-0.40%-0.17%
LILLY CANADA ANNOUNCES AVAILABILITY OF MOUNJARO® KWIKPEN® (TIRZEPATIDE INJECTION) IN ALL DOSES, ADVANCING CARE FOR ADULTS LIVING WITH TYPE 2 DIABETESPress releaseCanada Newswire-1.01%-1.34%
Darkness to Light Receives Grant from Direct Relief's Fund for Health Equity to Advance Prevention WorkPress releasePR Web+1.50%+3.93%
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of MedicinePress releasePR Newswire+1.50%+3.93%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground